Hematopoietic Cell Transplantation in a Patient With X‐Linked Chronic Granulomatous Disease With McLeod Phenotype
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70086 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Kentaro Fujimori und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: National Center for Child Health and Development.
Abstract (Originalsprache)
Background
X‐linked chronic granulomatous disease (X‐CGD) may be associated with McLeod syndrome (MLS) as a contiguous gene deletion syndrome. MLS is characterized by the loss of XK protein along with Kx antigen on red blood cell (RBC) surfaces and late‐onset neurocognitive symptoms. RBCs in healthy donors express XK protein and related Kx antigen on the surface; therefore, transfusion from random donors to patients with MLS poses a risk of Kx sensitization, leading to severe hemolysis. As the radical treatment of X‐CGD is hematopoietic cell transplantation (HCT), treating patients with coexisting X‐CGD and MLS is extremely challenging.
Method
A retrospective chart review was completed for a case of X‐CGD associated with MLS who underwent HCT.
Result
A 7‐year‐old boy with X‐CGD and MLS underwent HCT from a matched unrelated donor (human leukocyte antigen, 7/8 matched). Rituximab was added to busulfan‐based reduced intensity conditioning to prevent Kx sensitization. Donor RBCs were depleted from the bone marrow before infusion to prevent Kx sensitization. Neutrophil engraftment was achieved on day +19 with full donor chimerism. No hemolytic events occurred, and he is living well 2 years after HCT.
Conclusion
We were able to safely perform transplantation in a patient with X‐CGD and MLS by adding rituximab and depleting RBCs from the donor bone marrow. The long‐term impact of HCT on MLS is unclear. However, HCT may improve prognosis and quality of life by reducing recurrent infections caused by X‐CGD. Moreover, this HCT method is non‐invasive, relatively simple, and easily implementable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Immunology, National Center for Child Health and Development, Tokyo, Japan.
- Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
- Gene and Cell Therapy Promotion Center, National Center for Child Health and Development, Tokyo, Japan.
- Department of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo, Japan.
ORCID-Profile: Kentaro Fujimori, Takashi Ishikawa, Daisuke Tomizawa
Förderung
- National Center for Child Health and Development
Zitieren
APA
Fujimori, K., Shimizu, S., Ishikawa, T., Gocho, Y., Sakaguchi, H., Uchiyama, T., Nakabayashi, K., Tomizawa, D., Onodera, M., Matsumoto, K., Kawai, T., & Iguchi, A. (2025). Hematopoietic Cell Transplantation in a Patient With X‐Linked Chronic Granulomatous Disease With McLeod Phenotype. Pediatric Transplantation. https://doi.org/10.1111/petr.70086
Vancouver
Fujimori K, Shimizu S, Ishikawa T, Gocho Y, Sakaguchi H, Uchiyama T, et al. Hematopoietic Cell Transplantation in a Patient With X‐Linked Chronic Granulomatous Disease With McLeod Phenotype. Pediatric Transplantation. 2025. doi:10.1111/petr.70086
BibTeX
@article{Fujimori2025,
author = {Fujimori, Kentaro and Shimizu, Soichiro and Ishikawa, Takashi and Gocho, Yoshihiro and Sakaguchi, Hirotoshi and Uchiyama, Toru and Nakabayashi, Kazuhiko and Tomizawa, Daisuke and Onodera, Masafumi and Matsumoto, Kimikazu and Kawai, Toshinao and Iguchi, Akihiro},
title = {Hematopoietic Cell Transplantation in a Patient With X‐Linked Chronic Granulomatous Disease With McLeod Phenotype},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70086}
}
EUVIMED